Evidence map›Paper›PMID 35333531›Full record

ArticleMolecular pharmaceutics2022

Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy.

Veronique Beiss, Chenkai Mao, Steven N Fiering, Nicole F Steinmetz

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Virus nanotechnology for intratumoural immunotherapy.Nature reviews bioengineering · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Veronique BeissDepartments of NanoEngineering, University of California San Diego, La Jolla, California 92093, United States.
Chenkai MaoDepartment of Microbiology and Immunology, and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, New Hampshire 03756, United States.
Steven N FieringDepartment of Microbiology and Immunology, and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Health, Lebanon, New Hampshire 03756, United States.
Nicole F SteinmetzDepartments of NanoEngineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-0130-0481
Dartmouth–Hitchcock Medical Center · USUniversity of California San Diego · US

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.U01CA218292 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, STEINMETZ, NICOLE FRANZISKA · 2017 to 2021
$3.0M
NCI NIH HHS R01 CA224605NCI NIH HHS R01 CA253615NCI NIH HHS U01 CA218292
6 · The paper itself

Abstract

In situ vaccination for cancer immunotherapy uses intratumoral administration of small molecules, proteins, nanoparticles, or viruses that activate pathogen recognition receptors (PRRs) to reprogram the tumor microenvironment and prime systemic antitumor immunity. Cowpea mosaic virus (CPMV) is a plant virus that─while noninfectious toward mammals─activates mammalian PRRs. Application of CPMV as in situ vaccine (ISV) results in a potent and durable efficacy in tumor mouse models and canine patients; data indicate that CPMV outperforms small molecule PRR agonists and other nonrelated plant viruses and virus-like particles (VLPs). In this work, we set out to compare the potency of CPMV versus other plant viruses from the Secoviridae. We developed protocols to produce and isolate cowpea severe mosaic virus (CPSMV) and tobacco ring spot virus (TRSV) from plants. CPSMV, like CPMV, is a comovirus with genome and protein homology, while TRSV lacks homology and is from the genus nepovirus. When applied as ISV in a mouse model of dermal melanoma (using B16F10 cells and C57Bl6J mice), CPMV outperformed CPSMV and TRSV─again highlighting the unique potency of CPMV. Mechanistically, the increased potency is related to increased signaling through toll-like receptors (TLRs)─in particular, CPMV signals through TLR2, 4, and 7. Using knockout (KO) mouse models, we demonstrate here that all three plant viruses signal through the adaptor molecule MyD88─with CPSMV and TRSV predominantly activating TLR2 and 4. CPMV induced significantly more interferon β (IFNβ) compared to TRSV and CPSMV; therefore, IFNβ released upon signaling through TLR7 may be a differentiator for the observed potency of CPMV-ISV. Additionally, CPMV induced a different temporal pattern of intratumoral cytokine generation characterized by significantly increased inflammatory cytokines 4 days after the second of 2 weekly treatments, as if CPMV induced a "memory response". This higher, longer-lasting induction of cytokines may be another key differentiator that explains the unique potency of CPMV-ISV.

Indexed as

Cancer VaccinesComovirusNeoplasmsPlant VirusesSecoviridaeAnimalsCytokinesDogsHumansImmunotherapyMammalsMiceToll-Like Receptor 2Tumor MicroenvironmentCancer VaccinesCytokinesToll-Like Receptor 2cancer immunotherapycowpea mosaic virusin situ vaccineplant virussecoviridae

Identifiers

PMID35333531
PMCPMC9651057
OpenAlexW4221097686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.